Early-Stage Lung Cancer Diagnosis by a Point-of-Care Electrochemical Aptamer-Based Sensor of NAP2 in Human Serum
Analytical Chemistry · 2025
DOI: 10.1021/acs.analchem.4c06815 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, 2025. Verfasst von Baixun He und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical College, Tianjin University, Tianjin 300072, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Aptamers, Nucleotide, Electrochemical Techniques, Point-of-Care Systems. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The target neutrophil-activating peptide-2, NAP2, is a potential biomarker for early lung cancer diagnosis, whereas there are currently no precise techniques for differentiating NAP2 from its precursors. To overcome this difficulty, we created an electrochemical aptamer-based sensor (E-AB) consisting of the 33-mer aptamer domain, a 2-bp three-junction region, and two conductive signal reporter stems. Whereas E-AB-AT and E-AB-RAN sensors with two (AT)6 or N12 stems, respectively, were unable to distinguish between platelet basic protein (PBP) (94 aa) and NAP2 (70 aa). However, in contrast, the E-AB-GC sensor with two (GC)6 stems could selectively detect NAP2 but hardly recorded PBP. Here, we developed an E-AB-GC point-of-care test (POCT) technique to detect NAP2 away from its precursors in 10 μL of human serum and provide concentration data in 5 min. Interestingly, serum NAP2 levels in human samples, as determined by the E-AB-GC sensor, were roughly 30-50% lower than those obtained by ELISA. Results also showed that E-AB-GC analysis of serum NAP2 in patients in stages I through IV revealed statistical significance and an excellent guiding function in the early diagnosis of lung cancer, particularly for patients in stage I cancer (p = 0.0054, area under the curve, 0.95). Importantly, this E-AB-GC POCT platform has shown potential as an on-site quick diagnostic tool, which can also be used to detect other lung cancer markers. Our research on the impacts of stem sequencing on sensing capabilities might assist in the future development of E-AB biomarker sensors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical College, Tianjin University, Tianjin 300072, China.
- Department of Clinical Laboratory, Tianjin Union Medical Center of Nankai University, Tianjin 300121, China.
- Department of Clinical Laboratory, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, China.
ORCID-Profile: Shuang Li, Cherie S Tan
Förderung
- National Natural Science Foundation of China
Zitieren
APA
He, B., Fu, J., Chen, C., Zhang, W., Li, S., Tan, C. S., & Ming, D. (2025). Early-Stage Lung Cancer Diagnosis by a Point-of-Care Electrochemical Aptamer-Based Sensor of NAP2 in Human Serum. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.4c06815
Vancouver
He B, Fu J, Chen C, Zhang W, Li S, Tan CS, et al. Early-Stage Lung Cancer Diagnosis by a Point-of-Care Electrochemical Aptamer-Based Sensor of NAP2 in Human Serum. Analytical Chemistry. 2025. doi:10.1021/acs.analchem.4c06815
BibTeX
@article{He2025,
author = {He, Baixun and Fu, Jie and Chen, Chong and Zhang, Wenxin and Li, Shuang and Tan, Cherie S and Ming, Dong},
title = {Early-Stage Lung Cancer Diagnosis by a Point-of-Care Electrochemical Aptamer-Based Sensor of NAP2 in Human Serum},
journal = {Analytical Chemistry},
year = {2025},
doi = {10.1021/acs.analchem.4c06815}
}
EUVIMED